Paroxysmal atrial arrhythmias occur in myotonic dystrophy type 1 (MD1) patients frequently. Pacemaker (PM) including detailed diagnostic functions may facilitate the diagnosis and management of frequent paroxysmal atrial tachyarrhythmias that may remain undetected during conventional clinical follow-up. Aim of our study was to evaluate the preventive effects of interatrial septum pacing in the Bachmann's Bundle region on atrial fibrillation (AF) in MD1 patients during 12 months follow up period.
Introduction
Myotonic dystrophy (MD) is a serious autosomal-dominant hereditary disease with an estimated incidence of 1 in 8000 births. 1 -3 This disorder is characterized by highly variable clinical manifestation 4 that affects specific tissues, such as distal limb and facial muscles, smooth muscles (gastrointestinal tract, uterus), the eye (primarily the lens), and the brain (especially the anterior temporal and frontal lobes), as well as endocrine function (testosterone deficiency, abnormal growth hormone regulation, insulin resistance). The cardiac involvement is noticed in 80% of cases, and it often precedes the skeletal muscle one. Heart block is the first and most clinically significant cardiac disease in this group of patients and it is related to fibrosis of the conduction system and fatty infiltration of the His bundle. 5 To prevent cardiac sudden death, implantation of a pacemaker (PM) is required in 3-22% of cases. 6 Paroxysmal atrial arrhythmias (atrial fibrillation, atrial flutter, atrial tachycardia) occur in MD1 patients frequently. PM including detailed diagnostic functions may facilitate the diagnosis and management of frequent paroxysmal atrial tachyarrhythmias that may remain undetected during conventional clinical follow-up. 7 Aim of our study was to evaluate the preventive effects of interatrial septum pacing in the BB region on atrial fibrillation (AF) in MD1 patients during 12-months follow-up period.
Methods

Study population
We studied 30 MD1 patients (age 50.3 + 7.3; 11 F) who underwent dual chamber PM implantation in our division, which were randomized at implantation to receive right atrial appendage pacing (16 patients) or Bachmann's bundle pacing (14 patients) . No statistically significant difference in the electrical parameters (P wave amplitude, pacing threshold and lead impedance) was found between the RRA site and the BB region at implantation. Before implantation of PM, physical examination, 12-lead electrocardiogram (ECG), 24-h ECG Holter monitoring, echocardiogram and invasive electrophysiological study (EPS) were performed. All MD1 patients with foramen ovale, atrial septal aneurysm, severe mitral stenosis, left atrial enlargement, paroxysmal atrial fibrillation (PAF) or who have undergone prior surgery involving the RA (coronary bypass or valvular heart surgery) were excluded from the study. The indication for PM implantation was first-degree atrioventricular block with a pathological infra-Hissian conduction in 15 patients, symptomatic second-or third-degree atrioventricular block, respectively in 11 and 4 patients. All patients were not taking any antiarrhythmic medications. The study was conducted according to the declaration of Helsinki. Written informed consent was obtained from the patients before implant as approved by the institution's medical ethical committee.
PM system and programmed parameters
Standard technique for implantation of a dual-chamber PM system (Medtronic Kappa D901, or Adapta ADDR01, Medtronic Inc., Minneapolis, MN, USA) was used. Percutaneous subclavian vein cannulation was performed in all cases. First, the right ventricular lead (Medtronic 4074 CapSure Sense) was positioned in the apex, under fluoroscopic guidance. All MD1 patients received the bipolar atrial screw-in pacing lead CapSureFix w 5076 (Medtronic Inc., Minneapolis, MN, USA). The electrode surface material consists of titanium -nitride alloy with an electrode surface area of 4.2 mm 2 for the helix and of 22 mm 2 for the ring electrode. There is 1-mg dexamethasone in the electrode tip, which elutes after lead implantation. The distance between the two electrodes is 10 mm. The atrial pacing lead position was randomized in the right atrial appendage or on the right side of the interatrial septum in the region of Bachmann's bundle. All the devices are programmed in DDDR mode. The lower rate was set to 70 bpm. Rate adaptive pacing was used with a maximum rate of 130 bpm. Mode switches were programmed to occur for atrial rates .200 bpm persisting for more than 6 ventricular beats. All the special algorithms to prevent atrial fibrillation were disabled. The devices used in this study were programmed to detect episodes of atrial tachycardia, and to record summary and detailed data, including atrial and ventricular electrogram.
The endpoints
The endpoints assessed in our study were the number and the total duration of AF episodes between RAA and BB pacing in MD1 patients during 12 months follow-up.
Follow-up
Patients were discharged 2 days post-implantation after confirming the electrical lead parameters. If required, the reprogramming was done to adjust atrial sensitivity and to optimize AV synchronous pacing. They were reexamined for the status of the wound at the site of PM implantation after 10 + 2 days. Patients were followed at 1, 4 and 12 months thereafter. They underwent clinical assessment, a standard 12-lead ECG, and assessment of device performance at every visit. We counted the number of episodes of atrial arrhythmia occurred during the collection period and the duration of each episode after 12 months of follow-up.
Statistical analysis
Continuous variables are expressed as mean + standard deviation. Statistical analysis was performed using Student's t-test for unpaired data and Fisher's exact test for comparing proportions. P-values ,0.05 were considered to be statistically significant. Analyses were performed using the statistical package SPSS 11.0 software for Windows SPSS Inc., (Chicago, IL, USA).
Results
The baseline characteristics of the study population are provided in Table 1 . All patients completed 12 months follow-up. During the follow-up period, nine MD1 patients (age 47.3 + 5.9; 4 F) with a percentage of atrial stimulation lower than 80% were excluded from the evaluation. At 12 months follow-up, the population study consisted of two groups: Group RAA (n: 11; age 55.2 + 7; 4 F) with atrial lead placed in the right atrial appendage; Group BB (n: 10; age 49.2 + 7.5; 2 F) with atrial lead placed in the Bachmann's bundle region. There were no statistically significant differences between the age and sex composition of the groups and the medication intake. The number and the total duration of AF episodes, the ventricular pacing rates are shown in Table 2 . No statistically significant differences were found in the number and the duration of AF episodes between the RAA and BB group ( Figure 1A-B ). There were more episodes and longer durations of AF in patients paced in the RAA than BB, but this did not reach statistical significance. This difference tended to become larger after 12 months of follow-up compared with 6 months of follow-up. No statistically significant difference in ventricular pacing rate between the groups was shown. There was no significant difference in the atrial pacing capture, sensing threshold and atrial lead impedances at implant and at 12 months follow-up ( Table 3) . Lead parameters remained stable over time and there were no lead-related complications.
Discussion
In our clinical experience, MD1 patients who underwent PM implantation manifested during follow-up period a high number of paroxysmal atrial arrhythmias. According to the data in the literature, our observations confirm their frequent occurrence in patients with myotonic dystrophy. 8 Several studies 9 -11 have documented that cardiac involvement in MD1 patients is not limited to the specialized conduction system, as initially proposed, and a cardiac myopathy, characterized by the progressive selective fibrosis and scar replacement of initially unaffected areas, may be part of this disease. This anatomopathological substrate may facilitate the onset and the perpetuation of atrial fibrillation in MD1 patients. Atrial pacing may prevent the onset of atrial fibrillation through the following mechanisms: prevention of the relative bradycardia that triggers paroxysmal AF; prevention of the bradycardia-induced dispersion of refractoriness; suppression or reduction of premature atrial contractions that initiate re-entry and predispose to AF; and preservation of atrioventricular synchrony, which may prevent switch-induced changes in atrial repolarization, predisposing to AF. 12, 13 According to our previous study, 14 the atrial lead insertion in the interatrial septum in region of Bachmann's bundle is a safe procedure and is affected by a low rate of sensing and pacing defects in MD1 patients. The aim of our prospective, randomized study was to compare the longterm preventive effects on atrial fibrillation between the interatrial septum pacing, in the Bachmann's bundle region, and the conventional right appendage atrial pacing in MD1 patients. To minimize the confounding variables with different electrode materials and interelectrode spacing, the identical model lead was used in all the patients. Similarly, PMs with identical behaviour and telemetric capabilities were used to assure accuracy in comparing measurements between patients.
Bachmann's bundle pacing
BB is a group of muscular fibres that originate in the crest of the crista terminalis near the sinus node and across the roof of the atrial septum. BB diverges into fibres in the anterior and posterior left atrium. more rapidly than the surrounding myocardium. 11 The role of BB pacing in prevention of atrial fibrillation is still controversial. Bailin et al. 15 showed that, in patients with sinus bradycardia and PAF, interatrial septum pacing at the Bachmann's bundle significantly decreased the progression to chronic atrial fibrillation when compared with RAA pacing. Yu et al. 16 showed that, in patients with PAF, single-site pacing at either Bachmann's bundle, right posterior inter-atrial septum near the coronary ostium and distal coronary sinus are similar and more effective than biatrial or dual-site atrial pacing in preventing the induction of AF with right atrial appendage stimulation. Nevertheless, in a larger multicentre, randomized study, the Atrial Septal Pacing Efficacy Clinical trial (ASPECT), 17 septal pacing did not diminish AF frequency or burden in spite of reducing PACs. 14 These results were confirmed by Hakacova et al. 18 that did not find a significant difference in the number of AF episodes and the duration of AF between septal vs. high atrial pacing group. Katsivas et al. 19 in a randomized controlled study showed that atrial septal pacing does not prevent AF episodes in patients requiring atrial pacing for sinus node dysfunction when AF episodes are not documented in the 3 months before pacing. A beneficial effect is suggested in the subgroup of patients with ≥1 AF episode in the last 3 months before pacing. According to previous studies, 20 far field R-waves (FFRS) and oversensing were frequent in septal pacing, especially with a longer tip-to-ring spacing. 21, 22 Reducing the interelectrode distance reduces the incidence of FFRS and improves the ratio between the P-wave and FFRS amplitudes. 23 Lewicka-Nowak et al. 24 showed that Bachmann's bundle area features optimal conditions for signal sensing, and such atrial lead positioning may offer advantages to prevent oversensing of R-wave, our results in MD1 patients confirms these findings.
Main findings
The main findings of our study are that there was no significant difference in the occurrence of AF in MD1 patients during any of the pacing treatment assignments. The potential reasons of these findings in MD1 patients are that the specific histopathological pattern, characterized by diffuse fibrosis, myocyte hypertrophy and fatty acid infiltration, should reduce the potential benefit effects of the BB stimulation on the symmetry of atrial activation and on the atrial activation and recovery time. Further studies that explains our study results are necessary to evaluate the fibrosis pattern in MD1 patients, the atrial refractoriness during BB pacing and its correlation with AF incidence.
Limitations
The small number of patients included is certainly a limitation and a more extensive study is needed to confirm these preliminary data.
The episode detection criteria used in this study (atrial rate .200 min-1 for six or more ventricular beats) included short arrhythmias with limited clinical relevance. No specific analysis of sensing during AF has been made.
Conclusion
In a 12-months follow-up comparison between the right atrial appendage and Bachmann's bundle atrial pacing, we did not demonstrate a significant effect of BB stimulation in the reduction of atrial fibrillation in MD1 patient. No atrial pacing and sensing defects or electrodes displacement were found. Based on these short-term follow-up data, it is concluded that in MD1 patients Bachmann's bundle stimulation is a safe and feasible procedure, but it does not seem to provide significant benefit for prevention of PAF. A long-term follow-up study is necessary to confirm our data.
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